Kymera Therapeutics (NASDAQ:KYMR) Shares Down 7% – What’s Next?

Kymera Therapeutics, Inc. (NASDAQ:KYMR)’s stock price was down 7% during trading on Monday . The stock traded as low as $111.24 and last traded at $111.0490. 140,821 shares were traded during trading, a decline of 81% from the average daily volume of 759,974 shares. The stock had previously closed at $119.35.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. B. Riley Financial lifted their price target on Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Royal Bank Of Canada downgraded Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and increased their price objective for the company from $106.00 to $115.00 in a research note on Monday. Bank of America raised their price objective on Kymera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $121.73.

Kymera Therapeutics Trading Down 7.9%

The company has a fifty day moving average price of $90.61 and a two-hundred day moving average price of $84.32. The firm has a market capitalization of $9.04 billion, a price-to-earnings ratio of -30.79 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.18. The firm had revenue of $34.37 million during the quarter, compared to analysts’ expectations of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The business’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.82) earnings per share. As a group, equities research analysts expect that Kymera Therapeutics, Inc. will post -3.28 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Bruce N. Jacobs sold 77,109 shares of the business’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $114.96, for a total transaction of $8,864,450.64. Following the transaction, the chief financial officer owned 244,883 shares of the company’s stock, valued at approximately $28,151,749.68. The trade was a 23.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bvf Partners L. P/Il sold 1,578,800 shares of the business’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $106.50, for a total transaction of $168,142,200.00. Following the transaction, the director directly owned 240,123 shares in the company, valued at approximately $25,573,099.50. The trade was a 86.80% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 3,661,505 shares of company stock worth $392,385,535 in the last quarter. 15.98% of the stock is currently owned by insiders.

Institutional Trading of Kymera Therapeutics

Hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC increased its holdings in shares of Kymera Therapeutics by 27.5% during the 2nd quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock worth $52,000 after buying an additional 98 shares during the last quarter. US Bancorp DE grew its position in Kymera Therapeutics by 9.8% in the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock worth $106,000 after acquiring an additional 166 shares during the period. Glenmede Trust Co. NA increased its stake in Kymera Therapeutics by 3.6% during the first quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock worth $565,000 after acquiring an additional 235 shares during the last quarter. Cetera Investment Advisers increased its stake in Kymera Therapeutics by 7.5% during the first quarter. Cetera Investment Advisers now owns 3,602 shares of the company’s stock worth $300,000 after acquiring an additional 252 shares during the last quarter. Finally, Larson Financial Group LLC raised its position in Kymera Therapeutics by 36.9% in the fourth quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock valued at $83,000 after purchasing an additional 287 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.